Jeffrey Rosenfeld, PhD

Tonix Pharmaceuticals
Chatham, NJ, United States

Presentation(s):

• 1833: Development of a Polygenic Risk Model for Therapeutic Response to Bedtime Sublingual Cyclobenzaprine (TNX-102 SL*) in Fibromyalgia Based on Polygenic Single Nucleotide Polymorphism (SNP)-Count Scores

  Tuesday, November 14, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.